Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report
- 16 September 2009
- journal article
- case report
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 65 (12) , 1169-74
- https://doi.org/10.1007/s00228-009-0723-7
Abstract
Fibrates are used to manage mixed dyslipidemia. However, these drugs have the potential risk of inducing rhabdomyolysis. This paper gives an overview of the literature on rhabdomyolysis associated with fibrate therapy.Keywords
This publication has 75 references indexed in Scilit:
- Combination statin–fibrate therapy: safety aspectsDiabetes, Obesity and Metabolism, 2008
- Hypothyroidism is a Predisposing Factor for Fenofibrate Induced Rhabdomyolysis - Patient Report and Literature ReviewDrug Metabolism and Drug Interactions, 2007
- Myotoxicity associated with lipid-lowering drugsCurrent Opinion in Rheumatology, 2007
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2006
- Olanzapine overdose is associated with acute muscle toxicityHuman & Experimental Toxicology, 2006
- A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidismClinical Nephrology, 2005
- Cerivastatin and Reports of Fatal RhabdomyolysisNew England Journal of Medicine, 2002
- Rhabdomyolysis and Acute Renal Failure Associated with Gemfibrozil TherapyNephron, 1996
- Bezafibrate induced rhabdomyolysis.Annals of the Rheumatic Diseases, 1992
- Clofibrate-Induced Muscle Damage with Myoglobinuria and CardiomyopathyNew England Journal of Medicine, 1977